2:53 PM
 | 
Oct 11, 2018
 |  BC Extra  |  Politics & Policy

Inter Partes Review to be more favorable to biotech

The U.S. Patent and Trademark Office (PTO) finalized a rule requiring higher standards for invalidating patents through inter partes review (IPR) petitions, a victory for biopharma companies and other industries that depend on strong patent rights. The...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >